title: Eltrombopag for resistant immune thrombocytopenia secondary to chronic lymphocytic leukaemia.
abstract: Autoimmune manifestations are a common occurrence with chronic lymphocytic leukaemia (CLL). We describe a case of CLL-associated immune thrombocytopenia (ITP) that had a loss of response to standard treatment for ITP. The thrombopoeitin receptor agonist, eltrombopag, was successfully used preoperatively to increase the platelet count to a safer level, in this instance to facilitate laparoscopic splenectomy.
authors.affiliation: Wellington Blood and Cancer Centre, Capital and Coast District Health Board, Wellington, New Zealand.
authors.forename: E
authors.initials: E
authors.lastname: Jolliffe
authors.forename: K
authors.initials: K
authors.lastname: Romeril
mesh_terms: D001565:Benzoates / Q000627:therapeutic use*; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy* / Q000209:etiology*; D011720:Pyrazoles / Q000627:therapeutic use*
chemical_list: D001565:Benzoates; D006834:Hydrazines; D011720:Pyrazoles; C520809:eltrombopag
keywords: chronic lymphocytic leukaemia; eltrombopag; immune thrombocytopenia; thrombopoeitin receptor agonist